Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 5;6(3):203-216.
doi: 10.1158/2643-3230.BCD-24-0274.

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma

Camila Guerrero #  1 , Maria-Jose Larrayoz #  1 , Irache Erdozain  1 , Noemi Puig  2 , Maria-Teresa Cedena  3 , Catarina Maia  1 , Amagoia Mañu  1 , Natalia Gordillo  1 , Oihane Churruca  1 , Diego Alignani  1 , Sarai Sarvide  1 , Iria Vazquez  1 , Cristina Perez  1 , Albert Oriol  4 , Laura Rosinol  5 , Rafael Ríos-Tamayo  6 , Marta-Sonia Gonzalez-Perez  7 , Ana-Pilar Gonzalez-Rodriguez  8 , Felipe de Arriba  9 , Jose M Moraleda  10 , Jesus Martin  11 , Luis Palomera  12 , Valentin Cabañas  10 , Maria-Jose Calasanz  1 , Joaquin Martinez-Lopez  3 , Maria-Victoria Mateos  2 , Joan Bladé  5 , Juan-Jose Lahuerta  3 , Jesus F San-Miguel  1 , Bruno Paiva  1
Affiliations

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma

Camila Guerrero et al. Blood Cancer Discov. .

Abstract

SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.

PubMed Disclaimer

Conflict of interest statement

N. Puig reports personal fees from Amgen, Bristol Myers Squibb, Takeda, The Binding Site, Sanofi, and Menarini and grants from Pfizer outside the submitted work. M.-T. Cedena reports personal fees from Johnson&Johnson and Sobi outside the submitted work. A. Oriol reports personal fees from Sanofi, Pfizer, Amgen, GlaxoSmithKline, Bristol Myers Squibb, Johnson&Johnson, and Oncopeptides outside the submitted work. L. Rosinol reports other support from Janssen, Bristol Myers Squibb, Sanofi, Takeda, GlaxoSmithKline, Menarini Stemline, and Pfizer outside the submitted work. F. de Arriba reports personal fees and nonfinancial support from Janssen-Cilag, Bristol Myers Squibb/Celgene, Amgen, GlaxoSmithKline, and Sanofi outside the submitted work. V. Cabañas reports grants and personal fees from Johnson&Johnson and personal fees from Bristol Myers Squibb, Amgen, Biogene, GlaxoSmithKline, Menarini, and Sanofi outside the submitted work. M.-V. Mateos reports personal fees from Johnson&Johnson, Bristol Myers Squibb, GlaxoSmithKline, Sanofi, Pfizer, Kite, Stemline, Oncopeptides, AbbVie, and Roche outside the submitted work. J.F. San-Miguel reports other support from Abbvie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, and SecuraBio outside the submitted work. B. Paiva reports personal fees from Adaptive, Amgen, and Becton Dickinson, grants and personal fees from Sanofi, Takeda, Bristol Myers Squibb–Celgene, and Janssen, and personal fees from Merck, Novartis, and Roche outside the submitted work. No disclosures were reported by the other authors.

References

    1. Ragon BK, Shah MV, D’Souza A, Estrada-Merly N, Gowda L, George G, et al. . Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv 2023;7:2746–57. - PMC - PubMed
    1. Avivi I, Vesole DH, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, et al. . Outcome of second primary malignancies developing in multiple myeloma patients. Cancers (Basel) 2023;15:4359. - PMC - PubMed
    1. Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, et al. . Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine 2023;62:102099. - PMC - PubMed
    1. Pasvolsky O, Bashir Q. Autologous transplant and second malignancies in MM. Blood Adv 2023;7:2731–2. - PMC - PubMed
    1. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. . Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms. Blood 2022;140:1753–63. - PMC - PubMed

LinkOut - more resources